600511 China National Medicines Corporation
- 34.75
- +0.09+0.26%
China National Medicines Corporation News
Sinopharm Co., Ltd. (600511): Steady growth in performance and continued improvement in profitability
Event: The company released its 2024 quarterly report, and its performance continued to grow steadily. In the first quarter of 2024, the company achieved operating income of 12.122 billion yuan, a year-on-year increase of 7.98%, and net profit to mother of 459 million yuan, a year-on-year increase
Sinopharm Co., Ltd. (600511): Net profit slightly exceeds expectations, traditional business is expected to grow steadily
Net profit for the first quarter of 2024 slightly exceeded our expectations. The company announced the results for the first quarter of 2024: revenue of 12.12 billion yuan, up 7.98% year on year; net profit to mother of 460 million yuan, corresponding to profit per share of 0.61 yuan.
Sinopharm Co., Ltd. (600511): 2024Q1 results are in line with expectations, net investment income increased 30% year-on-year
Incident: The company released its 2024 quarterly report. In the first quarter of 2024, it achieved operating income of 12.122 billion yuan (yoy +8%), achieved net profit of 459 million yuan (yoy +11%), deducted net profit from non-return to mother
Express News | Sinopharm shares: net profit of 459 million yuan in the first quarter, up 10.86% year on year
Haitong International released a research report on April 10 stating that Sinopharm shares (600511.SH) were given an superior market rating, and the target price was 47.60 yuan. The main reasons for the rating include: 1) revenue growth of 9.23% in 2023,
Haitong International released a research report on April 10 stating that Sinopharm shares (600511.SH) were given an superior market rating, and the target price was 47.60 yuan. The main reasons for the rating include: 1) revenue growth of 9.23% in 2023, and net profit growth of 9.26%; 2) the direct sales business in Beijing grew steadily, and the market position continued to lead; 3) the national distribution business continued to grow and the quality of operation in the industrial sector improved; 4) the leading position in the distribution of hemp essence drugs was stable, and the profit contribution of joint ventures was steady. (Mainichi Keizai Shimbun)
Individual Investors Own 29% of China National Medicines Corporation Ltd. (SHSE:600511) Shares but Private Companies Control 56% of the Company
Key Insights The considerable ownership by private companies in China National Medicines indicates that they collectively have a greater say in management and business strategy 55% of the company is
Sinopharm Co., Ltd. (600511): Steady annual revenue growth and gradual improvement in operating quality
In 2023, revenue increased 9.23%, and net profit to mother increased 9.26%. In 2023, the company's revenue was 49.696 billion yuan, up 9.23% year on year; net profit to mother was 2.146 billion yuan, year-on-year
Zheshang Securities: An important new business format that is currently breaking the pharmaceutical market, the future of the CSO sector may support the growth of relevant industry targets, etc.
The Zhitong Finance App learned that Zheshang Securities released a research report stating that profitability is related to product IP ownership, product development stage, and CSO's empowerment of products. In the future, the profitability of the CSO business is expected to continue to improve as the product structure gradually matures and the proportion of its own IP products increases. At this stage, based on judging the current macroeconomic environment and the direction of continuous deepening of medical reform, the CSO sector is an important new business format for breaking the current pharmaceutical market. Changes in business trends may support the growth and profitability of the internal standards of the business format to exceed market expectations. Recommended attention: It has proven its own brand marketing capabilities, and has mature sales channels and capabilities
Sinopharm Co., Ltd. (600511: Performance is in line with expectations, maintains a leading edge in the narcotics sector
Core idea: The company publishes its 2023 annual report. In 2023, the company achieved revenue of 49.696 billion yuan (+9.23%, the following are all year-on-year ratios), net profit to mother of 2.46 billion yuan (+9.26%), deductions
Sinopharm Co., Ltd. (600511): The fee control effect is remarkable, and I am optimistic about steady growth throughout '24
Core idea On March 20, the company released its 2023 annual results report, achieving operating revenue of 49.696 billion yuan, a year-on-year increase of 9.23%, and net profit to mother of 2,146 billion yuan, an increase of 9.26% over the previous year.
Sinopharm Co., Ltd. (600511): 2023 profit slightly exceeded expectations, and the cost ratio was further optimized
2023 profit slightly exceeded our expectations. The company announced 2023 results: revenue of RMB 49.70 billion, up 9.2% year on year; net profit to mother of RMB 2.15 billion, corresponding to profit of 2.84 yuan per share, up year on year
Sinopharm's 2023 Profit Climbs 9%; Shares Up 6%
China National Pharmaceutical Group (SHA:600511) or Sinopharm recorded a net profit attributable to shareholders of 2.15 billion yuan, or 2.8443 yuan per share, in 2023, up 9.26% from the year-ago pro
A-share changes丨Sinopharm stock volume increased by more than 6%, Q4 net profit increased 28% year on year
Gelonghui, March 21 | Sinopharm shares (600511.SH) rose more than 6% to 31.4 yuan. The turnover increased to 458 million yuan, with a total market value of 23.69 billion yuan. The company announced yesterday after the market that it had achieved net profit of 2,146 billion yuan for the full year of 2023, an increase of 9.26% over the previous year. Among them, net profit for the fourth quarter was 684 million yuan, up 28.41% year on year. Furthermore, according to data from the Shanghai and Shenzhen Finance Group, Sinopharm received financing purchases of 11 million yuan yesterday, with a cumulative purchase amount of 36 million yuan over the past three days.
Express News | Sinopharm shares: net profit for 2023 increased 9.26% year-on-year, and plans to pay 10 to 8.54 yuan
China National Medicines (SHSE:600511) Might Be Having Difficulty Using Its Capital Effectively
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. In a perfect world, we'd like to see a company investing mor
Is China National Medicines (SHSE:600511) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to rui
Are Strong Financial Prospects The Force That Is Driving The Momentum In China National Medicines Corporation Ltd.'s SHSE:600511) Stock?
China National Medicines (SHSE:600511) has had a great run on the share market with its stock up by a significant 12% over the last three months. Since the market usually pay for a company's long-te
China National Medicines Deputy Manager Under Probe for Alleged Insider Trading
China National Medicines Corp. (SHA:600511) said its deputy general manager, Tang Lei, is being investigated by authorities for alleged insider trading. The company noted that the probe is related to
Shareholders in China National Medicines (SHSE:600511) Are in the Red If They Invested Three Years Ago
Many investors define successful investing as beating the market average over the long term. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns
Improved Earnings Required Before China National Medicines Corporation Ltd. (SHSE:600511) Shares Find Their Feet
With a price-to-earnings (or "P/E") ratio of 10.7x China National Medicines Corporation Ltd. (SHSE:600511) may be sending very bullish signals at the moment, given that almost half of all companies in
Analysis
Price Target
No Data
